These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 29247039

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
    Mellor HR.
    Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
    [Abstract] [Full Text] [Related]

  • 7. FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma.
    Huynh H, Prawira A, Le TBU, Vu TC, Hao HX, Huang A, Wang Y, Porta DG.
    Exp Mol Med; 2020 Nov; 52(11):1857-1868. PubMed ID: 33235319
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
    Lu X, Chen H, Patterson AV, Smaill JB, Ding K.
    J Med Chem; 2019 Mar 28; 62(6):2905-2915. PubMed ID: 30403487
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma.
    Rezende Miranda R, Fu Y, Chen X, Perino J, Cao P, Carpten J, Chen Y, Zhang C.
    J Med Chem; 2020 Oct 22; 63(20):11484-11497. PubMed ID: 33030342
    [Abstract] [Full Text] [Related]

  • 16. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
    Zhao H, Lv F, Liang G, Huang X, Wu G, Zhang W, Yu L, Shi L, Teng Y.
    Oncotarget; 2016 Mar 22; 7(12):13575-86. PubMed ID: 26498355
    [Abstract] [Full Text] [Related]

  • 17. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
    Shigesawa T, Maehara O, Suda G, Natsuizaka M, Kimura M, Shimazaki T, Yamamoto K, Yamada R, Kitagataya T, Nakamura A, Suzuki K, Ohara M, Kawagishi N, Umemura M, Nakai M, Sho T, Morikawa K, Ogawa K, Ohnishi S, Sugiyama M, Mizokami M, Takeda H, Sakamoto N.
    Carcinogenesis; 2021 Feb 11; 42(1):58-69. PubMed ID: 32449510
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
    Chen X, Liu Y, Zhang L, Chen D, Dong Z, Zhao C, Liu Z, Xia Q, Wu J, Chen Y, Zheng X, Cai Y.
    Eur J Med Chem; 2021 Mar 15; 214():113219. PubMed ID: 33618175
    [Abstract] [Full Text] [Related]

  • 20. FGF19-FGFR4 Signaling in Hepatocellular Carcinoma.
    Raja A, Park I, Haq F, Ahn SM.
    Cells; 2019 Jun 04; 8(6):. PubMed ID: 31167419
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.